Alphabet Inc. and its GV investment affiliates report a minority stake in Maze Therapeutics. As of December 31, 2025, they may be deemed to beneficially own 1,388,583 shares of Maze common stock, representing 2.9% of shares outstanding.
The holdings are split between GV 2019, L.P. with 784,019 shares (1.6%) and GV 2023, L.P. with 604,564 shares (1.3%), with control cascading through GV general partners to Alphabet subsidiaries and ultimately Alphabet Inc. The filing confirms ownership of 5% or less of the class.
Positive
None.
Negative
None.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
MAZE THERAPEUTICS, INC.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
578784100
(CUSIP Number)
12/31/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
578784100
1
Names of Reporting Persons
GV 2019, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
784,019.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
784,019.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
784,019.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.6 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP No.
578784100
1
Names of Reporting Persons
GV 2019 GP, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
784,019.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
784,019.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
784,019.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.6 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP No.
578784100
1
Names of Reporting Persons
GV 2019 GP, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
784,019.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
784,019.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
784,019.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.6 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP No.
578784100
1
Names of Reporting Persons
GV 2023, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
604,564.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
604,564.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
604,564.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.3 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP No.
578784100
1
Names of Reporting Persons
GV 2023 GP, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
604,564.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
604,564.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
604,564.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.3 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP No.
578784100
1
Names of Reporting Persons
GV 2023 GP, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
604,564.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
604,564.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
604,564.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.3 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP No.
578784100
1
Names of Reporting Persons
Alphabet Holdings LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,388,583.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,388,583.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,388,583.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.9 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP No.
578784100
1
Names of Reporting Persons
XXVI Holdings Inc.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,388,583.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,388,583.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,388,583.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.9 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP No.
578784100
1
Names of Reporting Persons
Alphabet Inc.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,388,583.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,388,583.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,388,583.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.9 %
12
Type of Reporting Person (See Instructions)
HC, CO
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
MAZE THERAPEUTICS, INC.
(b)
Address of issuer's principal executive offices:
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080.
Item 2.
(a)
Name of person filing:
GV 2019, L.P., a Delaware limited partnership (the "2019 Partnership")
GV 2019 GP, L.P., a Delaware limited partnership ("2019 GP")
GV 2019 GP, L.L.C., a Delaware limited liability company ("2019 LLC")
GV 2023, L.P., a Delaware limited partnership (the "2023 Partnership")
GV 2023 GP, L.P., a Delaware limited partnership ("2023 GP")
GV 2023 GP, L.L.C., a Delaware limited liability company ("2023 LLC")
Alphabet Holdings LLC, a Delaware limited liability company ("Alphabet Holdings")
XXVI Holdings Inc., a Delaware corporation ("XXVI")
Alphabet Inc., a Delaware corporation ("Parent" and, together with the 2019 Partnership, 2019 GP, 2019 LLC, the 2023 Partnership, 2023 GP, 2023 LLC, Alphabet Holdings, and XXVI, the "Reporting Persons")
(b)
Address or principal business office or, if none, residence:
1600 Amphitheatre Parkway
Mountain View, CA 94043
(c)
Citizenship:
Each of the Reporting Persons is formed, organized or incorporated, as applicable, in the State of Delaware.
(d)
Title of class of securities:
Common Stock, par value $0.001 per share
(e)
CUSIP No.:
578784100
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Reference to "beneficial ownership" of securities for purposes of this statement (this "Statement") shall be understood to refer to beneficial ownership as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").
As of December 31, 2025, the Reporting Persons may be deemed to beneficially own an aggregate 1,388,583 shares of the Common Stock of Maze Therapeutics, Inc. (the "Issuer").
As of December 31, 2025, the 2019 Partnership was the direct beneficial owner of 784,019 of the shares of the Issuer's Common Stock described in the preceding paragraph. 2019 GP is the general partner of the 2019 Partnership, and 2019 LLC is the general partner of 2019 GP. As such, 2019 GP and 2019 LLC may each be deemed to indirectly beneficially own the securities directly beneficially owned by the 2019 Partnership.
As of December 31, 2025, the 2023 Partnership was the direct beneficial owner of 604,564 of the shares of the Issuer's Common Stock described in the second paragraph of this Item 4(a). 2023 GP is the general partner of the 2023 Partnership, and 2023 LLC is the general partner of 2023 GP. As such, 2023 GP and 2023 LLC may each be deemed to indirectly beneficially own the securities directly beneficially owned by the 2023 Partnership.
Additionally: (i) Alphabet Holdings is the sole managing member of both 2019 LLC and 2023 LLC; (ii) XXVI is the sole managing member of Alphabet Holdings; and (iii) Parent is the controlling stockholder of XXVI. As such, as of December 31, 2025, for purposes of Section 13(d) of the Exchange Act, each of Alphabet Holdings, XXVI, and Parent may be deemed to indirectly beneficially own all of the Issuer's securities directly or indirectly beneficially owned by each of the other Reporting Persons, comprising an aggregate total of 1,388,583 shares of the Issuer's Common Stock.
Notwithstanding, the filing of this Statement shall not be construed as an admission that: (i) the 2019 Partnership, 2019 GP and 2019 LLC (collectively, the "2019 Affiliates"), on the one hand, or (ii) the 2023 Partnership, 2023 GP and 2023 LLC (collectively, the "2023 Affiliates"), on the other hand, is or has been, for purposes of Sections 13(d) or 13(g) of the Exchange Act, or for any other purpose, the direct or indirect beneficial owner of any of the Issuer's securities reported herein as beneficially owned by the other. The 2019 Affiliates and the 2023 Affiliates (each, an "Affiliate Group") expressly disclaim beneficial ownership of the securities beneficially owned by the other Affiliate Group.
(b)
Percent of class:
As of December 31, 2025, the Reporting Persons were deemed to directly or indirectly beneficially own an aggregate 2.9% of the Issuer's outstanding Common Stock. Of that percentage, beneficial ownership was attributable as follows: (i) 1.6%, directly to the 2019 Partnership and indirectly to each of 2019 GP and 2019 LLC; (ii) 1.3%, directly to the 2023 Partnership and indirectly to each of 2023 GP and 2023 LLC; and (ii) 2.9%, indirectly to each of Alphabet Holdings, XXVI, and Parent.
The aforementioned percentages were calculated in accordance with Rule 13(d)-3(d)(1)(i) promulgated under the Exchange Act and based on an aggregate total of 48,119,444 shares of the Issuer's Common Stock outstanding as of November 3, 2025 as reported by the Issuer in its Quarterly Report for the period ended September 30, 2025, filed with the SEC on Form 10-Q on November 6, 2025.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
Not Applicable
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
GV 2019, L.P.
Signature:
/s/ Inga Goldbard
Name/Title:
Inga Goldbard/General Counsel of GV 2019 GP, L.L.C., the General Partner of GV 2019 GP, L.P., its General Partner
Date:
02/06/2026
GV 2019 GP, L.P.
Signature:
/s/ Inga Goldbard
Name/Title:
Inga Goldbard/General Counsel of GV 2019 GP, L.L.C., its General Partner
Date:
02/06/2026
GV 2019 GP, L.L.C.
Signature:
/s/ Inga Goldbard
Name/Title:
Inga Goldbard/General Counsel
Date:
02/06/2026
GV 2023, L.P.
Signature:
/s/ Inga Goldbard
Name/Title:
Inga Goldbard/General Counsel of GV 2023 GP, L.L.C., the General Partner of GV 2023 GP, L.P., its General Partner
Date:
02/06/2026
GV 2023 GP, L.P.
Signature:
/s/ Inga Goldbard
Name/Title:
Inga Goldbard/General Counsel of GV 2023 GP, L.L.C., its General Partner
What ownership stake in MAZE does Alphabet report in this Schedule 13G/A?
Alphabet and its affiliated GV entities report beneficial ownership of 1,388,583 Maze Therapeutics common shares, equal to 2.9% of outstanding stock as of December 31, 2025. This reflects a minority, passive stake below the 5% large-shareholder threshold.
How are Alphabet’s MAZE shares allocated between GV 2019 and GV 2023 funds?
GV 2019, L.P. directly holds 784,019 Maze Therapeutics shares, representing 1.6% of the common stock. GV 2023, L.P. directly holds 604,564 shares, representing 1.3%. Alphabet’s higher-level entities may be deemed to indirectly own the combined 1,388,583-share position.
What percentage of MAZE’s outstanding shares is used to calculate Alphabet’s 2.9% stake?
The 2.9% beneficial ownership is calculated using 48,119,444 Maze Therapeutics common shares outstanding as of November 3, 2025. That outstanding share count comes from Maze’s Form 10-Q for the quarter ended September 30, 2025, filed with the SEC on November 6, 2025.
Do Alphabet and its GV affiliates claim more than 5% ownership of MAZE stock?
No. The filing states the reporting persons collectively beneficially own 2.9% of Maze Therapeutics common stock as of December 31, 2025. Item 5 confirms ownership of five percent or less of the class, indicating a relatively small, non-controlling equity position.
Which entities ultimately control Alphabet’s reported MAZE holdings?
GV 2019 and GV 2023 partnerships directly own the Maze shares, with their general partners and managing LLCs above them. Alphabet Holdings LLC, XXVI Holdings Inc., and Alphabet Inc. sit atop this structure and may be deemed to indirectly beneficially own the full 1,388,583-share position.
